Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $12
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $13 to $12.
Wells Fargo analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $13 to $12.